◀ Back to TYK2
JAK1 — TYK2
Pathways - manually collected, often from reviews:
-
BioCarta ifn alpha signaling pathway:
IFN-alpha/IFNAR1/IFNAR2/JAK1/TYK2 complex (IFNAR2-JAK1-IFNAR1-IFNA1-TYK2)
→
STAT1
(modification, activates)
-
BioCarta il22 soluble receptor signaling pathway:
IL-22/IL-22/IL-22R1/JAK1 complex (IL22-IL22RA1-JAK1)
→
IL-22/IL-22/IL-10R2C/TYK2 complex (IL22-IL10RA-TYK2)
(modification, collaborate)
-
BioCarta il22 soluble receptor signaling pathway:
IL-22/IL-22/IL-22R1/JAK1 complex (IL22-IL22RA1-JAK1)
→
IL-22/IL-22R1/IL-22/IL-22/IL-10R2C/TYK2/JAK1/JAK1/IL-22/IL-22R1/IL-22/IL-22/IL-10R2C/TYK2/IL-22/IL-22 complex (IL22-IL22RA1-IL10RA-TYK2-JAK1)
(modification, collaborate)
-
BioCarta il22 soluble receptor signaling pathway:
IL-22/IL-22/IL-10R2C/TYK2 complex (IL22-IL10RA-TYK2)
→
IL-22/IL-22R1/IL-22/IL-22/IL-10R2C/TYK2/JAK1/JAK1/IL-22/IL-22R1/IL-22/IL-22/IL-10R2C/TYK2/IL-22/IL-22 complex (IL22-IL22RA1-IL10RA-TYK2-JAK1)
(modification, collaborate)
-
BioCarta stat3 signaling pathway:
Stat3 activating cytokines/cytokine receptor/JAKs/TYK2 complex (JAK2_JAK1_JAK3-TYK2)
→
STAT3
(modification, activates)
-
BioCarta ifn alpha signaling pathway:
IFN-alpha/IFNAR1/IFNAR2/JAK1/TYK2 complex (IFNAR2-JAK1-IFNAR1-IFNA1-TYK2)
→
STAT2
(modification, activates)
-
BioCarta il22 soluble receptor signaling pathway:
STATs (STAT3/STAT5A/STAT1/STAT5A/STAT5B/STAT5B)
→
IL-22/IL-22R1/IL-22/IL-22/IL-10R2C/TYK2/JAK1/JAK1/IL-22/IL-22R1/IL-22/IL-22/IL-10R2C/TYK2/IL-22/IL-22 complex (IL22-IL22RA1-IL10RA-TYK2-JAK1)
(modification, collaborate)
-
BioCarta il22 soluble receptor signaling pathway:
IL-22/IL-22R1/IL-22/IL-22/IL-10R2C/TYK2/JAK1/JAK1/IL-22/IL-22R1/IL-22/IL-22/IL-10R2C/TYK2/IL-22/IL-22 complex (IL22-IL22RA1-IL10RA-TYK2-JAK1)
→
STATS/STATS complex (STAT3_STAT5A_STAT1_STAT5A_STAT5B_STAT5B)
(modification, activates)
-
BioCarta ifn alpha signaling pathway:
IFNAR2/TYK2 complex (TYK2-IFNAR2)
→
IFN-alpha/IFNAR1/IFNAR2/JAK1/TYK2 complex (IFNAR2-JAK1-IFNAR1-IFNA1-TYK2)
(modification, collaborate)
-
BioCarta ifn alpha signaling pathway:
IFNAR2/TYK2 complex (TYK2-IFNAR2)
→
IFNAR1/JAK1 complex (IFNAR1-JAK1)
(modification, collaborate)
-
BioCarta ifn alpha signaling pathway:
IFN-alpha/IFNAR1/IFNAR2/JAK1/TYK2 complex (IFNAR2-JAK1-IFNAR1-IFNA1-TYK2)
→
IFN-alpha (IFNA1)
(modification, collaborate)
-
BioCarta ifn alpha signaling pathway:
IFN-alpha/IFNAR1/IFNAR2/JAK1/TYK2 complex (IFNAR2-JAK1-IFNAR1-IFNA1-TYK2)
→
IFNAR1/JAK1 complex (IFNAR1-JAK1)
(modification, collaborate)
-
BioCarta ifn alpha signaling pathway:
IFNAR2/TYK2 complex (TYK2-IFNAR2)
→
IFN-beta/IFNAR1/IFNAR2/JAK1/TYK2 complex (IFNB1-TYK2-IFNAR2-IFNAR1-JAK1)
(modification, collaborate)
-
BioCarta ifn alpha signaling pathway:
IFNAR2/TYK2 complex (TYK2-IFNAR2)
→
IFNAR1/JAK1 complex (IFNAR1-JAK1)
(modification, collaborate)
-
BioCarta ifn alpha signaling pathway:
IFN-beta (IFNB1)
→
IFN-beta/IFNAR1/IFNAR2/JAK1/TYK2 complex (IFNB1-TYK2-IFNAR2-IFNAR1-JAK1)
(modification, collaborate)
-
BioCarta ifn alpha signaling pathway:
IFN-beta/IFNAR1/IFNAR2/JAK1/TYK2 complex (IFNB1-TYK2-IFNAR2-IFNAR1-JAK1)
→
IFNAR1/JAK1 complex (IFNAR1-JAK1)
(modification, collaborate)
-
BioCarta stat3 signaling pathway:
Stat3 activating cytokines/cytokine receptor/JAKs/TYK2 complex (JAK2_JAK1_JAK3-TYK2)
→
Cytokine receptor/JAKs/TYK2 complex (TYK2-JAK2_JAK1_JAK3)
(modification, collaborate)
-
Reactome Reaction:
JAK1
→
TYK2
(indirect_complex)
You et al., Mol Cell Biol 1999, Rani et al., J Biol Chem 1999, Mowen et al., Mol Cell Biol 2000, Myers et al., J Biol Chem 2001, Lamken et al., J Mol Biol 2004, Cajean-Feroldi et al., Biochemistry 2004, Roisman et al., J Mol Biol 2005, Geiger et al., J Virol 2006, Uzé et al., Curr Top Microbiol Immunol 2007, Xu et al., Frontiers in bioscience : a journal and virtual library 2008, Colamonici et al., Mol Cell Biol 1994, Improta et al., Proc Natl Acad Sci U S A 1994, Müller et al., Nature 1993, Yan et al., EMBO J 1996, Gauzzi et al., J Biol Chem 1996, Jiao et al., Mol Cell Biol 1996, Domanski et al., J Biol Chem 1997
-
Reactome Reaction:
JAK1
→
TYK2
(reaction)
Rani et al., J Biol Chem 1999, Mowen et al., Mol Cell Biol 2000, Lamken et al., J Mol Biol 2004, Cajean-Feroldi et al., Biochemistry 2004, Roisman et al., J Mol Biol 2005, Geiger et al., J Virol 2006, Uzé et al., Curr Top Microbiol Immunol 2007, Colamonici et al., Mol Cell Biol 1994, Improta et al., Proc Natl Acad Sci U S A 1994, Müller et al., Nature 1993, Yan et al., EMBO J 1996, Gauzzi et al., J Biol Chem 1996, Domanski et al., J Biol Chem 1997
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
-
IRef Biogrid Interaction:
TYK2
—
JAK1
(physical association, affinity chromatography technology)
Domanski et al., FEBS Lett 1995*
-
IRef Hprd Interaction:
TYK2
—
JAK1
(in vivo)
Domanski et al., FEBS Lett 1995*, Gauzzi et al., J Biol Chem 1996
-
IRef Hprd Interaction:
TYK2
—
JAK1
(in vitro)
Domanski et al., FEBS Lett 1995*, Gauzzi et al., J Biol Chem 1996
-
IRef Ophid Interaction:
TYK2
—
JAK1
(aggregation, confirmational text mining)
Domanski et al., FEBS Lett 1995*
-
IRef Ophid Interaction:
TYK2
—
JAK1
(aggregation, interologs mapping)
Brown et al., Bioinformatics 2005
Text-mined interactions from Literome
Shang et al., Cancer Sci 2007
(Carcinoma, Renal Cell...) :
The results suggest that the resistance of RCC to IFN-alpha is associated with the lack of Jak1,
Tyk2 and Stat1 expression and defective
Jak-Stat activation , but not with a lack of IFN-alpha receptor, suppressors of cytokine signaling induction or other factors examined
Simmons et al., J Virol 2009
:
Furthermore, at times when STAT1 activation was efficiently inhibited, VRP infection did not limit tyrosine phosphorylation of Jak1,
Tyk2 , or STAT2 after IFN-beta treatment but did
inhibit Jak1 and Jak2 activation in response to IFN-gamma, suggesting that VEEV interferes with STAT1 activation by the type I and II receptor complexes through distinct mechanisms
Dedoni et al., J Neurochem 2010
(Neuroblastoma) :
Janus kinase inhibition
reduced IFN-ß stimulated
TyK2 and STAT1 phosphorylation, STAT1 transcriptional activity, induction of double stranded RNA activated protein kinase ( PKR ) and caspase cleavage
Murata et al., J Biol Chem 1995
(Colonic Neoplasms) :
The phosphorylation of
JAK1 and JAK2 was
induced by IL-4 stimulation ; however,
Tyk2 was constitutively phosphorylated, and IL-4 treatment further augmented this phosphorylation
Eilers et al., Cell Growth Differ 1996
:
TYK2 activity
led to an IFN-alpha independent appearance of tyrosine phosphorylated STAT1 but not STAT2 or
JAK1 proteins